Pharmacology, Toxicology and Pharmaceutical Science
Antibiotic Agent
66%
Antibiotics
100%
Bacterial Infection
33%
Clinical Trial
33%
Combination Therapy
33%
Complement Component C5a
66%
Complement Component C5a Receptor
33%
Immunotherapy
100%
Infection
100%
Methicillin Resistant Staphylococcus Aureus Infection
33%
Mouse
33%
Murine
33%
Pharmacokinetics
33%
Porcine Model
33%
Virus Infection
33%
Keyphrases
Active C
10%
Antibiotics
10%
Antigen-presenting Cells
10%
Bacterial mutation
10%
Biologically Active
10%
C-terminal Region
10%
C5a Receptor
10%
C5aR
20%
CD88
10%
Clinical Development
10%
Clinical Trials
10%
Conventional Antibiotics
10%
Decapeptide
10%
EP67
50%
FDA-approved Drugs
10%
First Line of Defence
10%
Health Scenarios
20%
Host Innate Immune Response
10%
Host Innate Immunity
10%
Host-directed
50%
Human Population
10%
Human-relevant
10%
Immune Stimulation
20%
IND Application
10%
Industry Standards
10%
Innate Immune Response
10%
Methicillin-resistant Staphylococcus Aureus Infection
10%
Multidrug-resistant Infection
30%
Murine Model
10%
Mutational Pressure
10%
New Therapeutic Strategies
10%
One Health
10%
One Health Approach
50%
Pharmacokinetic Study
10%
Porcine Model
10%
Positive Impact
10%
Product Development
10%
Public Health
10%
Regulatory Evolution
10%
Regulatory Process
10%
Resistant Strains
20%
Safety Toxicity
10%
Specific Intent
10%
Structure Function
10%
Therapeutic Efficacy
10%
Therapeutic Framework
20%
Troubling
10%
Unmet Needs
10%
Viral Infection
10%
Medicine and Dentistry
Antibiotics
50%
Antigen Presenting Cell
10%
Bacterial Infection
10%
Bacterial Mutation
20%
Carboxy Terminal Sequence
10%
Clinical Trial
10%
Combination Therapy
10%
Complement Component C5a
20%
Complement Component C5a Receptor
10%
Immunotherapy
50%
Infection
30%
Innate Immunity
30%
Methicillin Resistant Staphylococcus Aureus Infection
10%
One Health
50%
Pharmacokinetics
10%
Public Health
10%
Virus Infection
10%